Affiliation: Cell Genesys
- AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastomaThomas C Harding
Cell Genesys, Inc, 500 Forbes Boulevard, South San Francisco, CA 94080, USA
Mol Ther 13:956-66. 2006..We propose that rAAV-mediated gene transfer of a potent soluble VEGF inhibitor in the CNS represents an effective antiangiogenic treatment strategy for GBM...
- Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectorsThomas C Harding
Cell Genesys, South San Francisco, CA 94080, USA
Hum Gene Ther 17:807-20. 2006....
- Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectorsMichael Robinson
Cell Genesys, Inc, 500 Forbes Blvd, South San Francisco, CA 94080, USA
J Virol 83:3450-62. 2009....
- Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapyKate L Dishart
Division of Cardiovascular and Medical Sciences, University of Glasgow, Church Street, G11 6NT, Glasgow, UK
J Mol Cell Cardiol 35:739-48. 2003..We have demonstrated for the first time the potential for third-generation lentiviral vectors, but not alternate AAV serotypes, as efficient vascular gene delivery vectors...